Form SCHEDULE 13G/A Phathom Pharmaceuticals, Filed by: JENNISON ASSOCIATES LLC
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St futures muted as oil gains curb risk appetite after S&P record close
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- Reddit to join S&P 500 index on Aug. 18, shares leap
Guggenheim on Phathom Pharmaceuticals (PHAT): 'Our NPV analysis suggests fair value in the $12-14 range'
June 6, 2025 1:46 PM EDTGuggenheim analyst Yatin Suneja reiterated a Buy rating and $12.00 price target on Phathom Pharmaceuticals (NASDAQ: PHAT).
The analyst comments "Recall that in Dec 2024, PHAT submitted a Citizen Petition (CP) to the FDA to formally request correction to the Orange Book listings for 10 mg... More
Phathom Pharmaceuticals (PHAT) PT Raised to $29 at Cantor Fitzgerald
June 6, 2025 1:16 PM EDTCantor Fitzgerald analyst Kristen Kluska raised the price target on Phathom Pharmaceuticals (NASDAQ: PHAT) to $29.00 (from $23.00) while maintaining a Overweight rating.
... MoreStifel Reiterates Buy Rating on Phathom (PHAT), PT $28, 'We leave our model unchanged, as our view reflected full 10-year exclusivity'
June 6, 2025 12:48 PM EDTStifel analyst Annabel Samimy reiterated a Buy rating and $28.00 price target on Phathom Pharmaceuticals (NASDAQ: PHAT).
The analyst comments "Voquezna Granted CP and Officially Gains 10-Year Exclusivity, Extending to 2032: Recall, last December PHAT filed a citizens petition/ CP to proactively nudge the FDA to update the Orange... More
